{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:02:42Z","timestamp":1792598562058,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier","isbn-type":[{"value":"9780128177389","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.01.003","type":"book-chapter","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T02:53:36Z","timestamp":1551840816000},"page":"141-163","source":"Crossref","is-referenced-by-count":11,"title":["Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years"],"prefix":"10.1016","author":[{"given":"Meng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiqian","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjiao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhe","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2019.01.003_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.pmbts.2018.12.004","article-title":"Serum SCCA Levels in patients suffering cancers or other diseases","volume":"162","author":"Yang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.pmbts.2018.12.005","article-title":"Increased serum CA724 levels in patients suffering gout vs. cancers","volume":"162","author":"Zhang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.pmbts.2018.12.006","article-title":"Serum CA50 levels in patients with cancers and other diseases","volume":"162","author":"Shan","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/bs.pmbts.2018.12.007","article-title":"CA242 as a Biomarker for Pancreatic Cancer and Other Diseases","volume":"162","author":"Dou","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2018.12.012","article-title":"Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers","volume":"162","author":"Zhang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/bs.pmbts.2018.12.010","article-title":"Serum CA199 levels are significantly increased in patients suffering liver, lung and other diseases","volume":"162","author":"Zeng","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/bs.pmbts.2019.01.005","article-title":"CA153 as a biomarker for cancer and other types of diseases","volume":"162","author":"Li","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.01.003_bb0045","first-page":"3663","article-title":"Comparative chemical structures of human alpha-fetoproteins from fetal serum and from ascites fluid of a patient with hepatoma","volume":"37","author":"Aoyagi","year":"1977","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.pmbts.2019.01.001","article-title":"Serum AFP levels in patients suffering 47 different types of cancers and non-cancer diseases","volume":"162","author":"He","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.121.3.439","article-title":"Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques","volume":"121","author":"Gold","year":"1965","journal-title":"J Exp Med"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.pmbts.2018.12.011","article-title":"Serum CEA levels in 49 different types of cancer and non-cancer diseases","volume":"162","author":"Hao","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.003_bb0065","first-page":"159","article-title":"Purification of a human prostate specific antigen","volume":"17","author":"Wang","year":"1979","journal-title":"Investig Urol"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/bs.pmbts.2018.12.013","article-title":"Serum PSA Levels in patients with prostate cancer and other 33 different types of diseases","volume":"162","author":"Gao","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.pmbts.2019.01.004","article-title":"Fasting blood glucose levels in patients with different types of diseases","volume":"162","author":"Zhang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/bs.pmbts.2019.01.008","article-title":"HbA1c: high in acute cerebral infarction and low in brain trauma","volume":"162","author":"Jiang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/bs.pmbts.2019.01.006","article-title":"Glycated albumin level is significantly decreased in patients suffering nephrotic syndrome","volume":"162","author":"Wang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.pmbts.2019.01.007","article-title":"Glycated serum proteins: high in pancreatic cancer and low in preeclampsia","volume":"162","author":"Wang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/bs.pmbts.2019.01.009","article-title":"The serum sialic acid levels are significantly increased in sepsis but decreased in cirrhosis","volume":"162","author":"Huang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pmbts.2018.12.001","article-title":"Desialylation in physiological and pathological processes\u2014new target for diagnostic and therapeutic development","volume":"162","author":"Wei","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/bs.pmbts.2018.12.008","article-title":"Serum \u03b1-l-fucosidase activities are significantly increased in patients with preeclampsia","volume":"162","author":"Zhang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/bs.pmbts.2018.12.009","article-title":"Glucuronidated bilirubin: significantly increased in hepatic encephalopathy and decreased in uremia","volume":"162","author":"Tang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2018.12.002","article-title":"Glycan-based biomarkers for diagnosis of cancers and other diseases: past, present and future","volume":"162","author":"Hu","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"6943","key":"10.1016\/bs.pmbts.2019.01.003_bb0120","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1136\/bmj.308.6943.1552","article-title":"Diagnostic tests. 1: sensitivity and specificity","volume":"308","author":"Altman","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/bs.pmbts.2019.01.010","article-title":"The sensitivity and specificity of serum glycan-based biomarkers for cancer detection","volume":"162","author":"Tang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.01.003_bb0130","first-page":"2390","article-title":"Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers","volume":"6","author":"Lan","year":"2016","journal-title":"Am J Cancer Res"},{"issue":"160","key":"10.1016\/bs.pmbts.2019.01.003_bb0135","first-page":"1","article-title":"Tumor-dependent and -independent serum\/plasma biomarkers for early diagnosis of lung cancer","volume":"5","author":"Lu","year":"2016","journal-title":"Transl Med"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0140","doi-asserted-by":"crossref","first-page":"h3449","DOI":"10.1136\/bmj.h3449","article-title":"Tumour biomarkers: diagnostic, prognostic, and predictive","volume":"351","author":"Shaw","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.01.003_bb0145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1164\/rccm.201404-0603OC","article-title":"Assessment of a combined panel of six serum tumor markers for lung cancer","volume":"193","author":"Molina","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1373\/clinchem.2012.187047","article-title":"Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9","volume":"59","author":"Diamandis","year":"2013","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.01.003_bb0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tibtech.2007.02.006","article-title":"Moving cancer diagnostics from bench to bedside","volume":"25","author":"Zhang","year":"2007","journal-title":"Trends Biotechnol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.003_bb0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/10408363.2015.1075468","article-title":"Biomarker development, from bench to bedside","volume":"53","author":"Stenman","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2019.01.003_bb0165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2012.01.006","article-title":"Autoimmunity CMNiC. From bench to MS bedside: challenges translating biomarker discovery to clinical practice","volume":"248","author":"Rajasekharan","year":"2012","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.003_bb0170","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1373\/clinchem.2016.254649","article-title":"Waste, leaks, and failures in the biomarker pipeline","volume":"63","author":"Ioannidis","year":"2017","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1373\/clinchem.2012.185801","article-title":"Biomarker failures","volume":"59","author":"Ioannidis","year":"2013","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.003_bb0180","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1373\/clinchem.2009.127019","article-title":"The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification","volume":"56","author":"Makawita","year":"2010","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1373\/clinchem.2012.186940","article-title":"Conquering cancer in our lifetime: new diagnostic and therapeutic trends","volume":"59","author":"Diamandis","year":"2013","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.003_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ccell.2016.01.003","article-title":"A word of caution on new and revolutionary diagnostic tests","volume":"29","author":"Diamandis","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.01.003_bb0195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1074\/mcp.R400007-MCP200","article-title":"Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations","volume":"3","author":"Diamandis","year":"2004","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.003_bb0200","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1373\/clinchem.2013.209213","article-title":"Whole genome sequencing as a diagnostic test: challenges and opportunities","volume":"60","author":"Chrystoja","year":"2014","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0205","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1373\/clinchem.2012.184614","article-title":"The long journey of cancer biomarkers from the bench to the clinic","volume":"59","author":"Pavlou","year":"2013","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.01.003_bb0210","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1515\/cclm-2014-0317","article-title":"Present and future of cancer biomarkers","volume":"52","author":"Diamandis","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.003_bb0215","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/pr083696k","article-title":"Move over proteomics, here comes glycomics","volume":"7","author":"Srivastava","year":"2008","journal-title":"J Proteome Res"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0220","doi-asserted-by":"crossref","first-page":"601937","DOI":"10.1155\/2011\/601937","article-title":"Glycoproteomics-based identification of cancer biomarkers","volume":"2011","author":"Kim","year":"2011","journal-title":"Int J Proteomics"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.01.003_bb0225","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/0003-4819-115-8-623","article-title":"Clinical applications of serum tumor markers","volume":"115","author":"Bates","year":"1991","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14796694.1.1.37","article-title":"Cancer biomarkers: knowing the present and predicting the future","volume":"1","author":"Chatterjee","year":"2005","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.003_bb0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13547500600775011","article-title":"Biomarkers in cancer screening, research and detection: present and future: a review","volume":"11","author":"Kumar","year":"2006","journal-title":"Biomarkers"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.003_bb0240","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"issue":"5517","key":"10.1016\/bs.pmbts.2019.01.003_bb0245","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.003_bb0250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.01.003_bb0255","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.5858\/arpa.2013-0319-CR","article-title":"Lung cancer biomarkers: present status and future developments","volume":"137","author":"Cagle","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.01.003_bb0260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1756287213495915","article-title":"Biomarkers in prostate cancer surveillance and screening: Past, present, and future","volume":"5","author":"Cary","year":"2013","journal-title":"Ther Adv Urol"},{"issue":"9\u201310","key":"10.1016\/bs.pmbts.2019.01.003_bb0265","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/prca.201300024","article-title":"Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers","volume":"7","author":"Ju","year":"2013","journal-title":"Proteomics Clin Appl"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.01.003_bb0270","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1074\/mcp.R112.026799","article-title":"Developments in the identification of glycan biomarkers for the detection of cancer","volume":"12","author":"Ruhaak","year":"2013","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1354750X.2012.717105","article-title":"Potential biomarkers in gallbladder cancer: present status and future directions","volume":"18","author":"Srivastava","year":"2013","journal-title":"Biomarkers"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0280","first-page":"1","article-title":"Biomarkers for bladder cancer management: present and future","volume":"2","author":"Ye","year":"2014","journal-title":"Am J Clin Exp Urol"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.01.003_bb0285","first-page":"15","article-title":"The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements","volume":"8","author":"Gaudreau","year":"2016","journal-title":"Biomark Cancer"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.01.003_bb0290","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbagen.2016.01.013","article-title":"Glycomics and glycoproteomics focused on aging and age-related diseases\u2014glycans as a potential biomarker for physiological alterations","volume":"1860","author":"Miura","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.003_bb0295","doi-asserted-by":"crossref","first-page":"FSO72","DOI":"10.4155\/fso.15.72","article-title":"Biomarkers for prostate cancer: present challenges and future opportunities","volume":"2","author":"Sharma","year":"2016","journal-title":"Future Sci OA"},{"issue":"13","key":"10.1016\/bs.pmbts.2019.01.003_bb0300","doi-asserted-by":"crossref","first-page":"276","DOI":"10.21037\/atm.2017.05.13","article-title":"Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective","volume":"5","author":"Montagnana","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/bs.pmbts.2019.01.003_bb0305","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jprot.2018.04.016","article-title":"Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer","volume":"181","author":"Liu","year":"2018","journal-title":"J Proteome"},{"issue":"Pt 1","key":"10.1016\/bs.pmbts.2019.01.003_bb0310","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semcancer.2017.08.010","article-title":"Prognostic and predictive biomarkers in breast cancer: past, present and future","volume":"52","author":"Nicolini","year":"2018","journal-title":"Semin Cancer Biol"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117319300146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T07:49:44Z","timestamp":1606636184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117319300146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177389"],"references-count":61,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.01.003","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}